A Survey of Brentuximab Vedotin in Pediatric Participants with Hodgkin Lymphoma
Not Applicable
Recruiting
- Conditions
- Hodgkin Lymphoma
- Registration Number
- JPRN-jRCT2031220244
- Lead Sponsor
- Contact for Clinical Trial Information
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
1.Treatment-naive participants
2.CD30 positive participants
3.Participants treated with the study drug in combination with doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD).
4.Participants aged < 18 years at the start of this drug.
Exclusion Criteria
Participants with contraindications to the study drug.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Percentage of Participants who Experienced Myelosuppression<br>Time Frame: Up to 26 Weeks<br><br>2.Percentage of Participants who Experienced Peripheral Neuropathy<br>Time Frame: Up to 26 Weeks<br><br>3.Percentage of Participants who Experienced Lung Disorder<br>Time Frame: Up to 26 Weeks
- Secondary Outcome Measures
Name Time Method